PRESS-RELEASE ·Filed Mar 18, 2026

ONMD

OneMedNet Corporation
MIXED
Impact 5/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release: contract
Actionable Insight ◆ Mixed

Monitor for future customer wins, commercial adoption of the integrated platform, or expanded use in AI training and regulatory submissions; absence of near-term financials limits immediate trading catalysts.

DirectionMixed
Confidencemedium
Horizonmonths
Final — all horizons settled through T+60d
ONMD ▼ -28.69% at T+60d
NEUTRAL call ✗ call lost -28.69% · α vs SPY -40.22% · entry $0.8190 → $0.5840
Entry anchored
Mar 17, 03:59 PM ET
via exchange tick
T+1d
-2.93%
call -2.93% · α -2.66%
$0.7950
settled 7mo ago
T+5d
+5.74%
call +5.74% · α +6.45%
$0.8660
settled 6mo ago
T+20d
+8.30%
call +8.30% · α +2.26%
$0.8870
settled 6mo ago
T+60d
-28.69%
call -28.69% · α -40.22%
$0.5840
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

OneMedNet Corporation (ONMD) announced a strategic collaboration with Navidence to integrate Navidence's Computable Operational Definitions (CODefs) into OneMedNet's iRWD™ platform, aiming to streamline real-world data access for life sciences research. The partnership targets efficiency, cost savings, and regulatory readiness in drug development, AI training, and real-world evidence generation, positioning OneMedNet to capture more value in the rapidly growing $1.88B real-world data market.

Key Facts

  • OneMedNet is collaborating with Navidence to integrate CODefs into its iRWD™ platform powered by Palantir Foundry.
  • The integration aims to improve cohort definition, data matching, and study execution speed for pharma and CROs.
  • No financial terms, revenue projections, or customer commitments were disclosed.
  • Forward-looking benefits include efficiency gains, cost savings, and regulatory advantages, but no quantified financial impact is provided.
  • Real-world data market projected to grow from $1.88B in 2025 to $6.37B by 2034 at 14.54% CAGR.

Financial Impact

Potential long-term revenue upside in a growing $6.37B market by 2034, but no immediate financial impact disclosed

revenueoperating efficiencymarket positioning

Risk Factors

  • Execution risk: Integration success depends on technical and commercial adoption by pharma/CRO clients.
  • Market competition: Other RWD providers may offer similar standardization tools.
  • No revenue or earnings impact disclosed — benefits are speculative and forward-looking.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258189
7 reports for ONMD
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +45.02%Jun 16, 2026
Filters
Rows
Reports for ONMD — sortable, filterable
TypeNow
Jul 24, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$0.6059 $0.5901▼ −2.61%▼ −5.91%$5.39 (+789.59%)
Jul 13, 2026
11w ago
EFFECT
NEUTRAL ★ 3/10
$0.7457 $0.6600▼ −11.49%▼ −14.68%$5.39 (+622.81%)
Jun 17, 2026
15w ago
Insider Cluster
BULLISH ★ 6/10
$0.6023 $0.6901▲ +14.58%▲ +13.26%$5.39 (+794.90%)
Jun 16, 2026
15w ago
Insider Cluster
BULLISH ★ 6/10
$0.5011 $0.7267▲ +45.02%▲ +44.82%$5.39 (+975.63%)
Apr 6, 2026
25w ago
Press Release
BULLISH ★ 8/10
$0.9520 $1.05▲ +10.29%▲ +1.31%$5.39 (+466.18%)
Apr 1, 2026
26w ago
Press Release
NEUTRAL ★ 4/10
$0.8440 $1.08▲ +27.96%▲ +18.24%$5.39 (+538.63%)
Mar 18, 2026
28w ago
Press Release
MIXED ★ 5/10
$0.8190 $0.8870▲ +8.30%▲ +2.26%$5.39 (+558.12%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (38h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 18, 2026